QLG2065 (semaglutide biosimilar)
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 26, 2026
A Phase I clinical study evaluating the safety, tolerability, and pharmacokinetic characteristics of QLM3017 in adult overweight/obese participants.
(chinadrugtrials.org.cn)
- P1 | N=60 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. / Qilu Antipharm Pharmaceutical Co., Ltd.
New P1 trial • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder
1 to 1
Of
1
Go to page
1